Research Article
Synergistic Effect between Cryptotanshinone and Antibiotics against Clinic Methicillin and Vancomycin-Resistant Staphylococcus aureus
Table 4
Synergistic effects of cryptotanshinone with vancomycin in isolated MRSA, VRSA, MSSA, and some of reference bacteria.
| | Samples | Agent | MIC/MBC (μg/mL) | FIC/FBC | FICI/FBCI2 | Outcome | | Alone | Combination1 |
| | MSSA ATCC 259233 | Cryptotanshinone | 64/256 | 16/64 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 0.5/2 | 0.125/0.5 | 0.25/0.25 | | MRSA ATCC 335914 | Cryptotanshinone | 4/16 | 1/4 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/4 | 0.25/1 | 0.25/0.25 | |
VRSA 3A0635 | Cryptotanshinone | 2/4 | 0.5/1 | 0.125/0.25 | 0.375/0.5 | Synergistic/synergistic | | Vancomycin | 16/32 | 4/8 | 0.25/0.25 | |
VRSA 3A0666 | Cryptotanshinone | 4/16 | 1/4 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 32/64 | 8/16 | 0.25/0.25 | | MSSA 17 | Cryptotanshinone | 16/64 | 4/16 | 0.25/0.25 | 0.5/0.75 | Synergistic/additive | | Vancomycin | 1/4 | 0.25/2 | 0.25/0.5 | | MSSA 2 | Cryptotanshinone | 32/128 | 8/16 | 0.25/0.125 | 0.5/0.625 | Synergistic/additive | | Vancomycin | 1/2 | 0.25/1 | 0.25/0.5 | | MRSA 18 | Cryptotanshinone | 16/32 | 4/8 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/2 | 0.25/0.5 | 0.25/0.25 | | MRSA 2 | Cryptotanshinone | 64/128 | 16/32 | 0.25/0.25 | 0.5/0.75 | Synergistic/additive | | Vancomycin | 2/4 | 0.5/2 | 0.25/0.5 | | MRSA 3 | Cryptotanshinone | 4/16 | 1/4 | 0.25/0.25 | 0.375/0.5 | Synergistic/synergistic | | Vancomycin | 2/4 | 0.25/1 | 0.125/0.25 | | MRSA 4 | Cryptotanshinone | 4/8 | 1/2 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/2 | 0.25/0.5 | 0.25/0.25 | | MRSA 5 | Cryptotanshinone | 64/128 | 16/32 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/2 | 0.25/0.5 | 0.25/0.25 | | MRSA 6 | Cryptotanshinone | 4/16 | 2/4 | 0.5/0.25 | 0.75/0.5 | Additive/synergistic | | Vancomycin | 1/2 | 0.25/0.5 | 0.25/0.25 | | MRSA 7 | Cryptotanshinone | 8/16 | 2/4 | 0.25/0.25 | 0.5/0.375 | Synergistic/synergistic | | Vancomycin | 1/4 | 0.25/0.5 | 0.25/0.125 | | MRSA 8 | Cryptotanshinone | 32/64 | 8/16 | 0.25/0.25 | 0.5/0.375 | Synergistic/synergistic | | Vancomycin | 1/4 | 0.25/0.5 | 0.25/0.125 | | MRSA 9 | Cryptotanshinone | 8/16 | 2/4 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/2 | 0.25/0.5 | 0.25/0.25 | | MRSA 10 | Cryptotanshinone | 16/64 | 4/8 | 0.25/0.25 | 0.5/0.75 | Synergistic/additive | | Vancomycin | 1/2 | 0.25/1 | 0.25/0.5 | | MRSA 11 | Cryptotanshinone | 8/32 | 2/8 | 0.25/0.25 | 0.75/0.5 | Additive/synergistic | | Vancomycin | 1/2 | 0.5/0.5 | 0.5/0.25 | | MRSA 12 | Cryptotanshinone | 4/8 | 1/2 | 0.25/0.25 | 0.5/0.375 | Synergistic/synergistic | | Vancomycin | 1/4 | 0.25/0.5 | 0.25/0.125 | | MRSA 13 | Cryptotanshinone | 32/128 | 16/32 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/2 | 0.25/0.5 | 0.25/0.25 | | MRSA 14 | Cryptotanshinone | 8/16 | 2/4 | 0.25/0.25 | 0.5/0.5 | Synergistic/synergistic | | Vancomycin | 1/4 | 0.25/1 | 0.25/0.25 | | MRSA 15 | Cryptotanshinone | 4/16 | 2/4 | 0.5/0.25 | 0.75/0.375 | Additive/synergistic | | Vancomycin | 1/4 | 0.25/0.5 | 0.25/0.125 | | MRSA 16 | Cryptotanshinone | 8/16 | 2/4 | 0.25/0.25 | 0.375/0.5 | Synergistic/synergistic | | Vancomycin | 1/2 | 0.125/0.5 | 0.125/0.25 |
|
|
1The MIC and MBC of cryptotanshinone with vancomycin.
2 The FIC index.
3MSSA (ATCC 25923): reference strain methicillin-sensitive Staphylococcus aureus.
4MRSA (ATCC 33591): reference strain methicillin-resistant Staphylococcus aureus.
5VRSA 3A063: vancomycin-resistant Staphylococcus aureus isolated clinically.
6VRSA 3A066: vancomycin-resistant Staphylococcus aureus isolated clinically.
7MSSA (1-2): methicillin-sensitive Staphylococcus aureus isolated clinically.
8MRSA (1–16): methicillin-resistant Staphylococcus aureus isolated clinically.
|
